Overview

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Status:
Recruiting
Trial end date:
2022-05-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide
Insulin Glargine